No known history of severe hypersensitivity reactions to any of the components of efatutazone or paclitaxel formulations
Patients disease must not have micropapillary components
Patient has a known hypersensitivity to any of the components of the study drug
Known hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin
Known hypersensitivity to the components of MM-, or docetaxel
Known hypersensitivity to any of the components of RO
For Part B exclusively, known hypersensitivity to any of the components of trastuzumab
For Part C exclusively, known hypersensitivity to any of the components of cetuximab
Known allergy, hypersensitivity, or contraindication to paclitaxel, docetaxel, or irinotecan or any components used in their preparation
Patients with known hypersensitivity to any of the components of CBL;
Known hypersensitivity to the components of niraparib components or their formulation excipients
Known hypersensitivity to ferumoxytol or any of its components
History of, or known, hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system.
Any known hypersensitivity or contraindication to the components of the study drug AZD
No known hypersensitivity or contraindication to the components of study treatment (M [VX-], gemcitabine)
Any known hypersensitivity or contraindication to the components of the study drug AZD
Patients with known hypersensitivity to any of the components of the PEGylated AuroShell suspension (polyethylene glycol, gold)
Known hypersensitivity to any of the components of M or eribulin.
Known hypersensitivity to any of the components of LMB- and/or SEL-
Subject has known sensitivity and immediate hypersensitivity to any components of AMG  or conditioning regimen (cyclophosphamide and fludarabine).
Known hypersensitivity to any of the components of cabozantinib or nivolumab
Participants with prior use of pirfenidone or known hypersensitivity to any of the components of study treatment will be excluded from the study
History of hypersensitivity to Vicinium or its components
Patients must not have a known hypersensitivity to the components of niraparib or the excipients
A known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil components
Patients with a known history of hypersensitivity to lomustine, dacarbazine, or any components of lomustine
Known hypersensitivity to any of the components of LMB-
Known hypersensitivity to any of the components of LMB-
Known hypersensitivity reactions to any of the components of Sym
Patients with known allergy or hypersensitivity to selinexor, sorafenib or any of its components
Known hypersensitivity to any of the components of talazoparib
Patients with known allergy or hypersensitivity to nivolumab, ipilimumab, -azacytidine, or any of their components
Known hypersensitivity to any of the products used in the trial  G-CSF (Neupogen, filgrastim), plerixafor (Mozobil), or any components of the chemotherapeutic agents or OBG/BCNU in vivo selection regimens
Patients with known hypersensitivity to any of the components of PFK-.
Known hypersensitivity to any of the components of MM- or other liposomal products
Tumor with ?% IDC components
Patient has known hypersensitivity to the components of study drug or its analogs
Patients with known hypersensitivity to the components of study drug or its analogs
Known hypersensitivity to enzalutamide or any of its components.
Patients with a history of or known hypersensitivity to melphalan or the components of the Melphalan/HDS system.
Have a history of hypersensitivity reaction to any of the components of Temozolomide
Has known hypersensitivity to Cremophor EL, paclitaxel or its components.
Any known hypersensitivity or contraindication to the components of the study drug AZD
Known hypersensitivity to any of the components of talazoparib
Any known hypersensitivity or contraindication to the components of the study drug AZD or olaparib.
Have a known hypersensitivity to any of the components of AG-, matched placebo, or azacitidine.
Known hypersensitivity to any of the components of tazemetostat
Known hypersensitivity to any of the products used in the trial-G-CSF (Neupogen), plerixafor, or any planned components of conditioning regimens
Known documented or suspected hypersensitivity to the components of the study drug(s) or analogs
Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C
Patients with known hypersensitivity to any of the components of oxaliplatin or mitomycin C
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to any of the components of RO and/or obinutuzumab
Hypersensitivity to ASTX, excipients of the drug product, or other components of the study treatment regimen.
Known hypersensitivity to any of the components of niraparib or prior hypersensitivity reactions to that class of drugs.
Known hypersensitivity reaction to temozolomide or any of its components, or dacarbazine (DTIC) if enrolled on ARM  or irinotecan or any of its components if enrolled on ARM 
Known hypersensitivity to any of the GTx- components or subjects previously received treatment with SARM
Has known hypersensitivity to any of the components of IP.
Subject has known hypersensitivity to immunoglobulins or any of the products or components to be administered during dosing.
Known hypersensitivity to any of the components of MM-, other liposomal products, fluoropyrimidines or leucovorin
Known hypersensitivity to the components of the study therapy or its analogs.
Patients with known allergy or hypersensitivity to lirilumab, -azacytidine, or any of their components; patients who have previously been treated with lirilumab in combination with -azacytidine will be excluded
Known hypersensitivity to any of the components of talazoparib
Known serious reactions or hypersensitivity to any components of the UV vaccine or similar peptide based vaccines
Known hypersensitivity to any of the components of talazoparib
Known hypersensitivity to the components of niraparib
Patients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitors
Subjects with known hypersensitivity to any of the components of AG-.
Subjects with known hypersensitivity to any of the components of AG-.
Known hypersensitivity to any components of the treatments
Patients with a known hypersensitivity to any of the components of the drug products
Patients with previous hypersensitivity reactions to the study drugs and components (ex: podophyllum and povidone).
Hypersensitivity to one or more of the TL- active components
History of hypersensitivity reactions to any components of the treatment regimen
Any known hypersensitivity to ofatumumab or its components.
Patient has known hypersensitivity to the components of study drug or its analogs
Known hypersensitivity to any of the components of MM- or who have had hypersensitivity reactions to fully human monoclonal antibodies
Patients with a known hypersensitivity to any of the components of the drug products
Has a known hypersensitivity to the components of the study treatment or its analogs.
Known hypersensitivity to cyclophosphamide, its metabolites or any other components, or known urinary outflow obstruction.
Known hypersensitivity to any of the components of RO
Patients with known hypersensitivity to any components of ME- or topotecan study drug product
Any known hypersensitivity or contraindication to the components of study treatment
Patients with known hypersensitivity to any of the components of AN- including doxorubicin and LH-RH agonists
Subjects with known hypersensitivity to any components of ALKS 
Subjects with known hypersensitivity to any components of pembrolizumab (for patients in combination arm only)
Known hypersensitivity to any of the treatment components of ramucirumab or LY.
Known hypersensitivity to the components of niraparib
Patient has a known hypersensitivity to any of the components of the study drug.
Known hypersensitivity to HDAC inhibitors or to any of the components of mocetinostat
Known hypersensitivity to any of the components of AG-
Patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel
Patients with a known or suspected hypersensitivity to any of the components of OTS.
Known hypersensitivity to any components of SCLD. study drug product.
Known significant hypersensitivity to any components of study treatment
Patients with a known or suspected hypersensitivity to either gemcitabine or any of the components of PRI-.
Hypersensitivity of AT or other components of the drug product
Known hypersensitivity to the components of niraparib, PD- inhibitor, or their excipients
Known hypersensitivity to the components of niraparib or excipients
Known hypersensitivity to any of the components of PRI-
Patients with a known hypersensitivity to any of the components of the drug products
History of allergies or known hypersensitivity to any components of melphalan or the components of the Melphalan/HDS system
Patients with known allergy or hypersensitivity to ponatinib, or -azacytidine, or any of their components
Known hypersensitivity to any of the components of talazoparib
Known or suspected hypersensitivity to any of the talazoparib capsule components.
Known or suspected hypersensitivity to any of the talazoparib capsule components.
Patient with known hypersensitivity to rocuronium, sugammadex or its components.
Participants with known hypersensitivity to modafinil, armodafinil, or any of its components
Patients with previous history of hypersensitivity to ribavirin or its components
History of hypersensitivity to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason
History of hypersensitivity to ribociclib or any of its components
Patients with hypersensitivity to sonazoid or one of its components
Hypersensitivity to CBT-, excipients of the drug product, or other components of the study treatment regimen.
Known hypersensitivity to the study drug or components of the preparation
Known hypersensitivity to Feraheme (ferumoxytol) or any of its components
Any known hypersensitivity or contraindication to the components of study treatment
Patients with known hypersensitivity to any of the components of PEGPH or cetuximab*
Patients may not have a known hypersensitivity to any of the components of ganetespib